← Back to patent-cliff list
CAS 155405-79-1
methyl 4-(3-bromo-4-oxobutyl)benzoate
Codes: PEME-014
Application context (from source-drug indications)
Non-small cell lung cancerPemetrexed Disodium Hydrate间皮组织肿瘤Pemetrexed Disodium Hydrate胸膜孤立性纤维瘤Pemetrexed Disodium HydrateBladder cancerPemetrexed Disodium HydrateUrothelial carcinomaPemetrexed Disodium HydrateSolid tumourPemetrexed Disodium Hydrate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Pemetrexed Disodium Hydrate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
methyl 4-bromobenzoate→but-3-yn-1-ol→methyl 4-(4-hydroxybut-1-yn-1-yl)benzoate→methyl 4-(4-hydroxybutyl)benzoate→methyl 4-(4-oxobutyl)benzoate→methyl 4-(3-bromo-4-oxobutyl)benzoate→2,6-diaminopyrimidin-4(3H)-one→methyl 4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoate→4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoic acid→diethyl (4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoyl)-L-glutamate compound with 4-methylbenzenesulfonamide (1:1)
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.